Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

被引：26

作者：

Ahn, M-J. ^{[1
]}

Niu, J. ^{[2
]}

Kim, D-W. ^{[3
]}

Rasco, D. ^{[4
]}

Mileham, K. F. ^{[5
]}

Chung, H. C. ^{[6
]}

Vaishampayan, U. N. ^{[7
]}

Maurice-Dror, C. ^{[8
]}

Lo Russo, P. ^{[9
]}

Golan, T. ^{[10
]}

Chartash, E. ^{[11
]}

Chen, D. ^{[11
]}

Healy, J. ^{[11
]}

Rajasagi, M. ^{[11
]}

Lee, D. H. ^{[12
]}

机构：

[1] Samsung Med Ctr, Med, Seoul, South Korea

[2] Banner MD Anderson Canc Ctr, Med Oncol, Gilbert, AZ USA

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[4] START Ctr Canc Care, Phase 1, San Antonio, TX USA

[5] Atrium Hlth Levine Canc Inst, Levine Canc Inst, Charlotte, NC USA

[6] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Med Oncol, Seoul, South Korea

[7] Karmanos Canc Ctr, Internal Med, Detroit, MI USA

[8] Rambam Hlth Care Campus, Oncol, Haifa, Israel

[9] Yale Canc Ctr, Med Oncol, New Haven, CT USA

[10] Sheba Med Ctr, Oncol, Ramat Gan, Israel

[11] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[12] Asan Med Ctr, Oncol, Seoul, South Korea

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.1714

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1400P

引用

页码：S887 / S887

页数：1